Sabby Management, LLC Aurinia Pharmaceuticals Inc. Transaction History

Sabby Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$10.0 - $14.52 $856,250 - $1.24 Million	-85,625 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$12.3 - $18.73 $365,088 - $555,943	29,682 Added 53.06%	85,625 $1.11 Million
Q4 2020 Feb 16, 2021	BUY	$12.94 - $16.05 $548,643 - $680,503	42,399 Added 313.05%	55,943 $774,000
Q3 2020 Nov 16, 2020	SELL	$13.19 - $16.66 $151,104 - $190,856	-11,456 Reduced 45.82%	13,544 $200,000
Q2 2020 Aug 14, 2020	SELL	$14.12 - $18.33 $247,100 - $320,774	-17,500 Reduced 41.18%	25,000 $406,000
Q1 2020 May 15, 2020	BUY	$11.34 - $21.46 $481,950 - $912,050	42,500 New	42,500 $617,000

208

58.6M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.24B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sabby Management, LLC with notifications on news.